PDE4A and chronic obstructive pulmonary disease: As selective inhibitors of PDE4 including rolipram, cilomilast and roflumilast are studied in clinical trials or licensed for use in COPD [34,124,125,126], targeting AKAP9-PDE4 complexes might be of benefit for COPD patients.